Thyroid Function Tests (TFTs): Rule out thyroid-related contributors to metabolic dysfunction
The 2025 trials asked something harder: whether the drugs already on the market, at the doses and in the populations studied, can slow human neurodegeneration, and for semaglutide in Alzheimers disease and exenatide in Parkinsons disease, the answer was no
cancer 122 (1), 8293
Control groups included sham, vehicle, GLP-1 R antagonist (exendin 9-39), GLP-1 R knockout/knockdown species, or additional medication (rtPA [recombinant tissue-type plasminogen activator], 46 warfarin, 49 metformin, canagliflozin, empagliflozin 35 )
The Microdose GLP-1 Protocol ($129/mo) provides a gentler entry point for anxiety-sensitive patients, allowing gradual adaptation